Differential redox proteomic profiles of serum from severe asthma patients after one month of benralizumab and mepolizumab treatment

Mepolizumab and Benralizumab are biological drugs for severe asthma patients able to reduce moderate-to-severe exacerbation rate (peripheral eosinophilial % mepolizumab 1.6 ± 1.2; benralizumab 0; p 

Saved in:
Bibliographic Details
Published in:Pulmonary pharmacology & therapeutics 2021-10, Vol.70, p.102060-102060, Article 102060
Main Authors: Landi, C., Vantaggiato, L., Shaba, E., Cameli, P., Carleo, A., d’Alessandro, M., Bergantini, L., Bargagli, E., Bini, L.
Format: Article
Language:English
Subjects:
Benralizumab
Mepolizumab
Redox proteomics
Serum
Severe eosinophilic asthma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mepolizumab and Benralizumab are biological drugs for severe asthma patients able to reduce moderate-to-severe exacerbation rate (peripheral eosinophilial % mepolizumab 1.6 ± 1.2; benralizumab 0; p 
ISSN:1094-5539
1522-9629
DOI:10.1016/j.pupt.2021.102060